Nautilus Reaches First Serono Deal Milestone

Nautilus Biotech has reached the first milestone in its collaboration with Serono to develop a next-generation human growth hormone with an improved pharmacological profile. The development of the next-generation human growth hormone (hGH) may allow less frequent injections of this important therapeutic protein, which is currently administered daily. Using its protein evolution technology, Nautilus has designed, generated and tested in vitro a series of proprietary variants of hGH.

Pharmaceutical Business Review (http://www.pharmaceutical-business-review.com/article_news.asp?guid=A8FC927F-5D78-4036-A82C-A0C06331DD4D)